Aarti Pharmalabs Q3 FY26 results: Rs 1.5 interim dividend declared
AARTIPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts less than Nifty Microcap 250 and 5.0 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Aarti Pharmalabs reported Q3 FY26 standalone revenue of about Rs 25,528 lakhs and net profit of Rs 4,384 lakhs. For 9M FY26, standalone PAT was Rs 12,599 lakhs versus Rs 16,850 lakhs in 9M FY25, a decline. Consolidated 9M FY26 PAT was Rs 12,801 lakhs versus Rs 18,063 lakhs. Board declared an interim dividend of Rs 1.50 per share (30 percent), record date Feb 16, 2026. Rs 4,935 lakhs of goods shipped but in transit, recorded as stock. Rs 279 lakhs exceptional provision made for new labour codes. Auditor Gokhale and Sathe flagged an emphasis of matter on the export cut-off treatment.
Interim dividend of Rs 1.50 per share is positive for shareholders. Year-on-year 9M profit decline may weigh on the stock despite sequential improvement.